AI
| Followers | 455 |
| Posts | 49989 |
| Boards Moderated | 4 |
| Alias Born | 02/23/2010 |
Monday, April 15, 2019 8:40:16 AM
SHMN Lets take a-LOOK@ what our New-CEO has-goin,,,on
Share Buy Back
$Revenue $397,688 first nine months of 2018, gross profit of $183,134
company currently has manageable capital for its operations
company has received its approval from OTCmarkets.com
Filed 3 years 9 months of Filings
Became "Pink Current"
revenue growth starting in 2019
Our manufacturing alliance partner operates a 20,000 square ft. Southern California facility that is FDA certified and OTC and Prescription (Rx) drug and cGMP compliant.
announced today the signing of a MASTER SUPPLY AGREEMENT with a US based customer
company's year 2019 revenue growth is expected up to 95% above the year 2018 figures.
expects more than 7 to 9 SKU orders from this customer
reentry into the US OTC retail
development of new products
plans to launch some more new product
generate sustainable revenue and rapid growth in 2019
expects some more orders from them during this quarter
expects its revenue growth more than doubling during the year 2019 compared to the year 2018 and overall profitability of around 38% during the year 2019.
Current revenue and orders are enough for its ongoing smooth operations
"Our operational and revenue generation efforts are ongoing, and we are confident of achieving our revenue target for the year 2019 and beyond", stated Mr. Night, President and CEO.
2018 Annual Due March 31,2019
Stop Sign LATE
4/4/2019 CEO Tweet Annual in coming days
What`s Above .002`s
***** My Call is .01 in 2019 *****
Share Buy Back
$Revenue $397,688 first nine months of 2018, gross profit of $183,134
company currently has manageable capital for its operations
company has received its approval from OTCmarkets.com
Filed 3 years 9 months of Filings
Became "Pink Current"
revenue growth starting in 2019
Our manufacturing alliance partner operates a 20,000 square ft. Southern California facility that is FDA certified and OTC and Prescription (Rx) drug and cGMP compliant.
announced today the signing of a MASTER SUPPLY AGREEMENT with a US based customer
company's year 2019 revenue growth is expected up to 95% above the year 2018 figures.
expects more than 7 to 9 SKU orders from this customer
reentry into the US OTC retail
development of new products
plans to launch some more new product
generate sustainable revenue and rapid growth in 2019
expects some more orders from them during this quarter
expects its revenue growth more than doubling during the year 2019 compared to the year 2018 and overall profitability of around 38% during the year 2019.
Current revenue and orders are enough for its ongoing smooth operations
"Our operational and revenue generation efforts are ongoing, and we are confident of achieving our revenue target for the year 2019 and beyond", stated Mr. Night, President and CEO.
2018 Annual Due March 31,2019
Stop Sign LATE
4/4/2019 CEO Tweet Annual in coming days
What`s Above .002`s
***** My Call is .01 in 2019 *****
~~~}((imgoingfishing ))* > http://investorshub.advfn.com/boards/board.aspx?board_id=22714
Asher Board http://investorshub.advfn.com/~-ASHER-~-25451/
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
